The below research that is considered a step to the cure for sickle cell disease could have importance for AD research as well. Providing proof of concept for a blood stem cell technology might allow a similar approach to be used to alter blood in those at risk of or with AD. (For example, eotaxin, blood transfusions from younger animals etc. have shown anti-AD effects.) There could be a range of possibilities to reduce dementia risk through CRISPRed blood. Perhaps even reduce amyloid levels?
What is especially exciting about this current research is that they are talking of moving this into the clinic over the next few years. Such a readily modifiable technology platform could benefit those with a range of illnesses.
https://www.sciencedaily.com/releases/2 ... 160205.htm
